Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Loss of Tumor Suppressor Gene Promotes Breast Cancer Metastasis into the Lungs

By BiotechDaily International staff writers
Posted on 08 Jun 2014
Image: Graphic explaining the consequences of the loss of function of RARRES3 for breast cancer lung metastasis (Photo courtesy of the Institute for Research in Biomedicine).
Image: Graphic explaining the consequences of the loss of function of RARRES3 for breast cancer lung metastasis (Photo courtesy of the Institute for Research in Biomedicine).
Cancer researchers have found that loss of a specific tumor suppressor gene promotes the metastasis of breast cancer cells into the lungs.

Investigators at the Institute for Research in Biomedicine (Barcelona, Spain) characterized the biological activity of RARRES3 (retinoic acid receptor responder protein 3), a recently identified metastasis suppressor gene whose reduced expression in primary breast tumors identifies a subgroup of patients more likely to develop lung metastasis. This work was carried out on samples from mice and in cell lines, and then was validated in 580 samples from human primary breast cancer tumors.

Results published in the May 27, 2014, online edition of the journal EMBO Molecular Medicine revealed that the loss of function of the RARRES3 gene in primary breast tumor cells promoted metastasis to the lung. RARRES3 downregulation engaged metastasis-initiating capabilities by facilitating adhesion of the tumor cells to the lung parenchyma. In addition, impaired tumor cell differentiation due to the loss of RARRES3 phospholipase A1/A2 activity also contributed to lung metastasis.

Looking at the results from the other direction, it was clear that the investigators had shown that RARRES3 blocked adhesion to the lung parenchyma and, second, the phospholipase activity of RARRES3 stimulated differentiation attributes, thus blunting metastasis-initiating functions at the lung required for the breast cancer cells to establish a lesion.

"RARRES3 is suppressed in estrogen receptor-negative (ER-) breast cancer tumors, thus stimulating the later invasion of the cancer cells and conferring them a greater malignant capacity," said senior author Dr. Roger Gomis, head of the growth control and cancer metastasis laboratory at the Institute for Research in Biomedicine. "The transformation of a normal cell into an invasive tumor cell is not just about acquiring capacities but equally important is the loss of certain genes, such as RARRES3."

Related Links:

Institute for Research in Biomedicine


Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.